Found this in the 10k did not know this part in red , very nice.
The sensor will collect a breath signature based upon chemical sensing technology residing in a small Bluetooth-enabled breathalyzer device that attaches to any smartphone. The sensor devices will ultimately be sold through a distributor to healthcare professionals, who will then download screening applications and pay a monthly subscription fee. Subsequently the company plans to sell direct to consumers in conjunction with a major pharmacy platform.
Vantage holds a sub-license to this technology which its parent company negotiated and executed. This sub-license includes a five-year, exclusive renewable worldwide license agreement with NASA to commercialize mobile healthcare products derived from the NASA patented chemical sensing technology in certain fields of use. The sensor technology was awarded the US Government NASA Invention of the year for 2012.
We have entered into a Strategic Partnership with Scripps Translational Sciences Institute (STSI) to assist in the development, advancement, and commercialization of the mobile technology. Scripps will also provide the testing, evaluation, and detection of certain combinations of Volatile Organic Compounds (VOCs) known as the breath signature and will assist in managing our clinical trials in partnership with several other research hospitals in the United States. These clinical trials will support the 510K that will be submitted to the FDA. It is expected that the contemplated clinical trials will take approximately four months with another four months expected for the 510K process within the FDA
News 
Market Data 
Discover 
